Evotec stock: FDA accepts second BMS drug candidate
Published on 11/21/2026 at 12:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvotec advances partnered drug pipeline
- The FDA accepted a second investigational drug candidate from Evotec's strategic partnership with Bristol Myers Squibb.
- The candidate is expected to enter a Phase 1 clinical trial in 2027.
Evotec and Bristol Myers Squibb advanced their strategic protein-degradation partnership on Thursday, November 19, after the U.S. Food and Drug Administration accepted a second Investigational New Drug application. The announcement, carried by Financial Times, said the candidate is a cereblon E3 ligase modulator, or CELMoD.
Second candidate moves toward trials
The candidate is expected to enter a Phase 1 clinical trial in 2027. The first candidate from the collaboration entered a Phase 1 trial in advanced clear cell renal cell carcinoma in March 2026.
The partnership combines Evotec's multi-omics screening, artificial-intelligence-supported analysis and drug-design capabilities with Bristol Myers Squibb's CELMoD compound library. Evotec said the collaboration is intended to build a pipeline of molecular-glue degraders for oncology and other therapeutic areas.
Weekly share performance remains weak
Evotec stock traded at 2.55 euros on Lang & Schwarz at 12:03 CET on Saturday, November 21, 1.76 percent above the Xetra close of Friday, November 20. MarketScreener lists the Xetra close at 2.506 euros on November 20; the prior Friday's close was 2.966 euros. The resulting weekly decline was 15.51 percent.
The FDA step expands the partnered pipeline, while the 2027 trial timetable leaves clinical development as the next material milestone for investors. The announcement does not provide a new financial forecast or a payment amount for the second candidate.
Evotec SE market facts
- Company: Evotec SE
- ISIN: DE0005664809
- Xetra ticker: EVT
- Sector: Biotechnology and Medical Research
- Lang & Schwarz quote: 2.55 euros at 12:03 CET on November 21, 2026
- Daily comparison: 1.76 percent above the Xetra close of 2.506 euros on November 20, 2026
- Weekly comparison: 2.966 euros on November 13 to 2.506 euros on November 20, 2026; down 15.51 percent
For broader German market context, see Current market reports.
More news and analyses on Evotec stock.
